116 related articles for article (PubMed ID: 11082152)
1. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan.
Lansang MC; Osei SY; Price DA; Fisher ND; Hollenberg NK
Hypertension; 2000 Nov; 36(5):834-8. PubMed ID: 11082152
[TBL] [Abstract][Full Text] [Related]
2. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus.
Lansang MC; Price DA; Laffel LM; Osei SY; Fisher ND; Erani D; Hollenberg NK
Kidney Int; 2001 Apr; 59(4):1432-8. PubMed ID: 11260405
[TBL] [Abstract][Full Text] [Related]
3. Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats.
Cervenka L; Wang CT; Mitchell KD; Navar LG
Hypertension; 1999 Jan; 33(1):102-7. PubMed ID: 9931089
[TBL] [Abstract][Full Text] [Related]
4. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
Price DA; De'Oliveira JM; Fisher ND; Hollenberg NK
Hypertension; 1997 Aug; 30(2 Pt 1):240-6. PubMed ID: 9260987
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
Cervenka L; Wang CT; Navar LG
Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
Buter H; Navis GY; Woittiez AJ; de Zeeuw D; de Jong PE
Eur J Clin Pharmacol; 1999 Feb; 54(12):953-8. PubMed ID: 10192757
[TBL] [Abstract][Full Text] [Related]
7. Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man.
Hollenberg NK; Osei SY; Lansang MC; Price DA; Fisher ND
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):14-8. PubMed ID: 11881058
[TBL] [Abstract][Full Text] [Related]
8. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
10. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
[TBL] [Abstract][Full Text] [Related]
11. Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction.
Nitescu N; Grimberg E; Guron G
Shock; 2008 Aug; 30(2):166-72. PubMed ID: 18091574
[TBL] [Abstract][Full Text] [Related]
12. Sodium intake influences hemodynamic and neural responses to angiotensin receptor blockade in rostral ventrolateral medulla.
DiBona GF; Jones SY
Hypertension; 2001 Apr; 37(4):1114-23. PubMed ID: 11304512
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in renal vascular response to angiotensin blockade with captopril or candesartan.
Forman JP; Price DA; Stevanovic R; Fisher ND
J Hypertens; 2007 Apr; 25(4):877-82. PubMed ID: 17351382
[TBL] [Abstract][Full Text] [Related]
14. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
Burnier M; Hagman M; Nussberger J; Biollaz J; Armagnac C; Brouard R; Weber B; Brunner HR
Hypertension; 1995 Apr; 25(4 Pt 1):602-9. PubMed ID: 7721404
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide participates in the renal vasodilatory effect of candesartan in anesthetized rats.
Demeilliers B; Mimran A; Jover B
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S208-12. PubMed ID: 9892165
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress.
Wuerzner G; Chioléro A; Maillard M; Nussberger J; Brunner HR; Burnier M
Kidney Int; 2004 Jan; 65(1):238-44. PubMed ID: 14675055
[TBL] [Abstract][Full Text] [Related]
17. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
18. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
Ruan X; Purdy KE; Oliverio MI; Coffman TM; Arendshorst WJ
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S202-7. PubMed ID: 9892164
[TBL] [Abstract][Full Text] [Related]
19. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
20. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Osei SY; Price DA; Laffel LM; Lansang MC; Hollenberg NK
Hypertension; 2000 Jul; 36(1):122-6. PubMed ID: 10904023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
